NRSN — Neurosense Therapeutics Share News
0.000.00%
Last trade - 00:00Brief: Neurosense Regains Compliance With Nasdaq Minimum Bid Price Rule
Brief: Neurosense Therapeutics - Positive Results Align With Co's Regulatory Strategy, Reinforce Long-Term Safety Profile Of Drug Candidate Primec
Brief: Neurosense Says Currently In Advanced Discussions With Several Multi-Billion-Dollar Pharma Cos For Potential Strategic Partnership
Brief: Neurosense Therapeutics Enters Into Capital On Demand Sales Agreement With Jonestrading Institutional Services
Neurosense Therapeutics Ltd expected to post a loss of 20 cents a share - Earnings Preview
Brief: Neurosense Therapeutics Says Paradigm ALS Clinical Trial Demonstrates Up To 73% Improved Complication-Free Survival
Brief: Neurosense Therapeutics Says Planning For Phase 3 Clinical Study In US And Europe
Brief: Neurosense Management Provides Corporate Update And First Quarter 2024 Financial Results
Neurosense Therapeutics Ltd reports results for the quarter ended in March - Earnings Summary
Brief: Neurosense Receives Delisting Notice From Nasdaq And Intends To Appeal
Neurosense Therapeutics Ltd expected to post a loss of 19 cents a share - Earnings Preview
Brief: NeuroSense Announces New Positive Data Analysis from PARADIGM Clinical Trial Demonstrating Statistically Significant Slowing of Disease Progression in High-Risk ALS Patients
Brief: Neurosense And Genetika+ Initiate Precision Medicine Collaboration
Brief: Neurosense Announces Pricing Of $4.5 Million Registered Direct Offering And Concurrent Private Placement
Brief: Biotech Firm NeuroSense Collaborates With Lonza To Identify Exosome-based Biomarkers
Neurosense Therapeutics Ltd expected to post a loss of 20 cents a share - Earnings Preview
Brief: Neurosense Reports Additional Positive Results From ALS Phase 2B Trial
Brief: Neurosense Regains Compliance With Nasdaq MBP Rule
Brief: Neurosense Therapeutics Expects To Report Results From Strategic Collaboration With Biogen Second Half Of January